CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
Sym015drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02648724
NCT02648724Phase 2Completed
CompareCT.gov

An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies

Symphogen A/S·interventional·Posted Jan 7, 2016·Updated Jun 22, 2022

In Brief

A Phase 2 clinical trial evaluating Sym015 for Oncology and 4 related conditions. Completed, enrolled 57 participants across 27 sites in 6 countries.

Detailed Summary

This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOncology, MET Gene Amplification, NSCLC, MET Gene Mutation, Non Small Cell Lung Cancer
CountriesDenmark, Hong Kong, South Korea, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 7, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.5 years ago

Interventions

Sym015drug

Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.